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OBJECTIVES: We examined the influence of CYP1A1 A4889G and T6235C polymorphisms on the risk of sporadic
breast cancer.
METHODS: DNA from 742 sporadic breast cancer patients and 742 controls was analyzed using the polymerase
chain reaction, followed by the restriction fragment length polymorphism technique.
RESULTS: More patients had the CYP1A1 4889AG+GG genotype compared to controls (29.0% versus 23.2%,
p=0.004). The G allele carriers had a 1.50-fold increased risk (95% CI: 1.14–1.97) of sporadic breast cancer
compared to the other study participants. The frequency of the 4889AG+GG genotype among the Caucasian
patients was higher than in the non-Caucasian patients (30.4% versus 20.2%, p=0.03) and controls (30.4% versus
23.2%, p=0.002). Caucasians and G allele carriers had a 1.61-fold increased risk (95% CI: 1.20–2.15) of sporadic
breast cancer compared to other subjects. The CYP1A1 4889AG+GG genotype was more common among patients
with a younger median age at first full-term pregnancy than among controls (33.8% versus 23.2%, p=0.001) and
subjects whose first full-term pregnancies occurred at an older age (33.8% versus 26.1%, p=0.03). Women with
the CYP1A1 4889AG+GG genotype and earlier first full-term pregnancies had a 1.87-fold (95% CI: 1.32–2.67)
increased risk of sporadic breast cancer compared to the other study participants. Excess CYP1A1 4889AG+GG
(39.8% versus 27.1%, p=0.01) and 6235TC+CC (48.4% versus 35.9%, p=0.02) genotypes were also observed in
patients with grade I and II tumors compared to patients with grade III tumors and controls (39.8% versus 23.2%,
p=0.04; 48.4% versus 38.6%, p=0.04). The G and C allele carriers had a 2.44-fold (95% CI: 1.48–4.02) and 1.67-fold
(95% CI: 1.03–2.69) increased risk, respectively, of developing grade I and II tumors compared to other subjects.
CONCLUSIONS: The CYP1A1 A4889G and T6235C polymorphisms may alter the risk of sporadic breast cancer in
Brazilian women.
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High-penetrance mutations account for a small proportion
of breast cancer (BC) cases (1) and several epidemiological
studies have indicated the involvement of low-penetrance
genetic polymorphisms in the pathophysiology of BC (2).
In addition to these genetic factors, compelling evidence
supports the role of systemic hypertension, tobacco, obesity
and exposure to polycyclic aromatic hydrocarbons (PAHs) in
BC formation through the promotion of DNA damage and
cell proliferation (3-6). Prolonged estrogen exposure is also
widely accepted as a risk factor for BC due to its mitotic
activity and increased mutation rates (7) and catechol
estrogens can be carcinogen metabolites (8,9). Hence, some
reproductive events, such as age at menarche, first-full term
pregnancy (FFTP) and menopause, may play important roles
in BC risk (10,11). Carriers of low-penetrance gene mutations,
combined with the above-mentioned factors, might have a
higher tumor risk (12,13).
The CYP1A1 gene (14) encodes the P450-1A1 (CYP1A1)
enzyme, which has aryl hydrocarbon hydroxylase activity.
This enzyme converts PAHs to aryl epoxides carcinogens.DOI: 10.6061/clinics/2015(10)04
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The enzyme also participates in estrogen metabolism by
catalyzing the 2-hydroxylation of estradiol, which results in
free radical and DNA adduct production (15). Two poly-
morphisms in this gene have been studied in relation to BC: an
A4889G substitution in exon 7 (rs1048943) and a T6235C
substitution in the 30 untranslated region (rs4646903) (16).
G and C allele variants yield enzymes with increased activities
in PAHs activation (17) and estrogen metabolism (18).
However, the role of these variants in BC risk in individuals
from the United States of America, Europe and Asia is still
controversial. Some studies have reported that G and C allele
variants increase BC risk (5,19-29), while other studies have not
observed main effects for CYP1A1 variants (3,5,19-22,25,27-37).
Regarding the clinical features and biological characteristics of
tumors, the impact of these genetic polymorphisms varies
(3,5,10,12,15,19-23,27,29-40). These contradictory findings
might be explained by the ethnic variations among popula-
tions and small study sample sizes (41).
The Brazilian population is highly heterogeneous and
consists of indigenous Amerindians and immigrants from
Europe, Asia and Africa (42). Cancer is the second most
common cause of death in the southeastern region of Brazil
and BC represents the most common cause of tumor death
among women (43). To the best of our knowledge, the role of
CYP1A1 A4889G and T6235C polymorphisms in the risk,
clinical features and biological characteristics of BC tumors is
unknown for people living in the Southern hemisphere.
Because large numbers of participants are needed worldwide
to examine the associations between a genetic polymorphism
and cancer risk, we analyzed the frequencies of the CYP1A1
A4889G and T6235C genotypes in large samples of BC
patients and controls from the southeastern region of Brazil.
We also investigated whether these genotypes influence the
risk of BC tumors in Brazil.
’ MATERIALS AND METHODS
Study population
We analyzed 742 consecutive female patients with sporadic
breast cancer (SBC) at diagnosis (median age, 53 years; range,
22–91 years; 638 Caucasians and 104 non-Caucasians). The
patients were treated at the Center of Integral Attention to
Women’s Health of the University of Campinas, Campinas/SP,
Brazil, from March 2004 to March 2007. The clinical features
were determined from a questionnaire, including age at
diagnosis, ethnic origin, age at menarche, age at FFTP and
age at menopause, lactation status, smoking habits, oral
contraceptives use and presence or absence of systemic
hypertension. The patients were considered to be smokers if
they kept smoking until the moment of diagnosis and the
patients were classified as non-smokers if they had never
smoked. The body mass index (BMI) was calculated according
to the World Health Organization classification and the patients
were classified into four groups: underweight, normal, pre-
obese and obese (44). BC was diagnosed through the
histological evaluation of tumor biopsies. The nuclear and
histological grades (45) and tumor stages (46) were established
according to conventional criteria. The expression levels of
estrogen and progesterone receptors were analyzed through
immunohistochemistry using the streptavidin-biotin complex
method (47) with estrogen receptor-clone 6F11 and progester-
one receptor-clone 6F16 antibodies (Novocastra Laboratories,
Tyne and Wear, Newcastle, UK).
The control group was composed of 742 healthy female
blood donors (median age, 40 years; range, 18–65 years; 638
Caucasians and 104 non-Caucasians) from the Centro de
Hematologia e Hemoterapia of the Universidade de Campi-
nas (during the same study period). These patients were
selected to represent the general population seeking medical
assistance in our region. The control group patients were
matched with the BC patients according to age and ethnicity.
Patients and controls with evidence of a personal or family
history of BC and patients who chose not to participate in the
study were excluded from the analyses. All procedures were
performed according to the Declaration of Helsinki and all
subjects provided written informed consent. The study was
approved by the local ethics committee (process number
581/2002).
Polymorphism analysis
The CYP1A1 A4889G (rs1048943) and T6235C (rs4646903)
genotypes were identified in genomic DNA from the
peripheral blood samples of subjects using the polymerase
chain reaction followed by restriction fragment length
polymorphism, as previously reported (48).
Statistical analyses
The Hardy-Weinberg (HW) equilibrium was tested using
chi-squared (w2) statistics for the goodness-of-fit (one degree
of freedom). The pairwise linkage disequilibrium (LD)
analysis was performed using Haploview 4.2 software
(www.broad.mit.edu/mpg/haploview) to ensure that the
markers were appropriate for inclusion in the haplotype
estimates. The LD was measured using the disequilibrium
coefficient (D0
́
) and strong LD significance was considered as
D0
́
X 80%. Between-group differences were analyzed with w2
or Fisher exact tests. A multivariate analysis using the
logistic regression model was used to obtain the age and
ethnic origin adjusted crude odds ratios (ORs) with 95%
confidence intervals (CI) and to assess the associations
between the genotypes and BC. A power of analysis (PA)
was used to calculate the minimum effect size likely to be
detected in a study using a given sample size, according to
Pocock (49) and Hulley et al. (50) in analyses involving
patients and controls and according to the DSS Research
statistical power calculators (51) when considering the
patients stratified by clinical and tumor characteristics.
The data analyses were performed with SPSS 15.0 software
(SPSS Incorporation, Chicago, IL, USA). For all statistical
tests, the level of significance was 2-sided at po0.05.
’ RESULTS
The patient and control samples were in HW equilibrium
at the CYP1A1 A4889G (w2=0.15, p=0.70; w2=1.15, p=0.28) and
T6235C (w2=2.65, p=0.10; w2=1.93, p=0.16) loci, respectively.
The LD analyses revealed a moderate LD between the
A4889G and T6235C polymorphisms of CYP1A1 (D0=73%),
and the referred polymorphisms were considered for further
analysis of the haplotypes.
More patients had the CYP1A1 4889AG (PA=87.0%) and
CYP1A1 4889AG+GG (PA=93.0%) genotypes compared with
the controls. Compared with the other study participants,
carriers of the CYP1A1 4889AG genotype had a 1.45-fold
increased risk of SBC and carriers of the CYP1A1 4889AG+GG
genotypes had a 1.50-fold increased risk. Similar frequencies of
the CYP1A1 T6235C genotypes and CYP1A1 haplotypes were
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observed in the patients and controls enrolled in the study
(Table 1).
The CYP1A1 4889AG and 4889AG+GG genotypes were
more common in the Caucasian SBC patients than in the
non-Caucasian patients (PA=73.0% and PA=57.3%, respec-
tively) and controls (27.9% versus 21.1%, p=0.002, PA=98%
and 30.4% versus 23.2%, p=0.002, PA=98%, respectively).
Caucasians with the CYP1A1 4889AG and 4889AG+GG
genotypes had a 1.61-fold and 1.61-fold increased risk of
tumors, respectively, than Caucasians with the remaining
genotypes, respectively. An excess of the CYP1A1 6235CC
genotype was observed in SBC patients with a lower median
age of menarche (younger than 13 years of age) compared
to patients who experienced menarche at a higher median
age (13 years of age and older, PA=55.3%). The CYP1A1
4889AG+GG genotype was more common among patients
with a lower median age at FFTP (younger than 22 years of
age) than among patients who experienced FFTP at a higher
median age (22 years of age and older) PA=58.6%). The
frequency of the CYP1A1 4889AG+GG genotype was higher
among patients with an earlier FFTP than among the controls
(33.8% versus 23.2%, p=0.001, PA499.0%). Women with the
CYP1A1 4889AG+GG genotype and FFTP occurring earlier in
life had a 1.87-fold increased risk of SBC compared to subjects
with the AA genotype. The frequency of the CYP1A1 6235CC
genotype in pre-obese and obese patients was higher than
in normal and underweight patients (PA=32.1%). Moreover,
the CYP1A1 4889AG (PA=77.1%), CYP1A1 4889AG+GG
(PA=69.3%) and CYP1A1 6235TC+CC (PA=63.0%) genotypes
were more common among patients with I and II histological
grade tumors than among patients with grade III tumors. The
frequencies of the respective genotypes in patients from the first
group were also higher than those observed in the controls
(37.6% versus 21.2%, po0.001, PA499.0%; 39.8% versus 23.2%,
po0.001, PA499.0%; 48.4% versus 38.6%, p=0.04, PA=95.0%).
Individuals with the CYP1A1 4889AG, CYP1A1AG+GG, and
CYP1A1 6235TC+CC genotypes had 2.48-, 2.44- and 1.67-fold
increased risks, respectively, for SBC compared to study
participants with the remaining genotypes (Table 2). Similar
frequencies of the CYP1A1 A4889G and T6235C genotypes
were observed among patients stratified by age at diagnosis,
age at menarche (younger than 12 years versus 12 years and
older), age at menopause and FFTP (younger than 30 years
versus 30 years and older), oral contraceptive use, lactation,
cigarette smoking habit, systemic hypertension, tumor histol-
ogy, stage and estrogen and progesterone receptor patterns.
The frequencies of the CYP1A1 haplotypes did not differ
among patients stratified by clinical and tumor features (data
not shown).
’ DISCUSSION
In this case-control study, we examined the influence of the
CYP1A1 A4889G and T6235C polymorphisms on the risk of
SBC. We also investigated whether these polymorphisms are
associated with the clinical features of SBC patients and with
the biological tumor characteristics.
We initially found that the CYP1A1 4889AG and 4889AG
+GG genotypes were associated with a higher risk of BC in
our cohort. Our results were consistent with the findings of
Chacko et al. (23), Singh et al. (36) and Surekha et al. (27)
(studies conducted in India). Ambrosone et al. (19) and
Ishibe et al. (5) also reported an increased risk of BC among
G variant allele carriers (with smoking habits) from the
United States of America. In fact, cytochrome P450 enzymes
encoded by the CYP1A1 gene play an important role in the
phase I bioactivation of xenobiotics and in the metabolism of
estrogen (converting the metabolites into carcinogens) (15).
G variant allele carriers of the CYP1A1 A4889G polymorph-
ism have a higher catalytic enzyme activity (17,18), which
results in a higher level of carcinogens in breast tissue and,
consequently, a higher level of DNA adducts, which may
serve as the initial step in BC development. In contrast with
our study, the CYP1A1 4889AG genotype was associated
Table 1 - CYP1A1 genotypes among sporadic breast cancer patients and controls.
Genotypes Patients Number (%) Controls Number (%) p-value OR* (95% CIa)
A4889G
AA 527 (71.0) 570 (76.8) reference
AG 195 (26.3) 157 (21.2) 0.01 1.45 (1.10-1.93)
GG 20 (2.7) 15 (2.0) 0.09 2.05 (0.89-4.71)
AA 527 (71.0) 570 (76.8) reference
AG+GG 215 (29.0) 172 (23.2) 0.004 1.50 (1.14-1.97)
AA+AG 722 (97.3) 727 (98.0) reference
GG 20 (2.7) 15 (2.0) 0.14 1.84 (0.81-4.20)
T6235C
TT 464 (62.5) 456 (61.5) reference
TC 236 (31.8) 243 (32.7) 1.00 1.00 (0.77-1.30)
CC 42 (5.7) 43 (5.8) 0.74 1.09 (0.65-1.83)
TT 464 (62.5) 456 (61.4) reference
TC+CC 278 (37.5) 286 (38.6) 0.90 1.01 (0.79-1.30)
TT+TC 700 (94.3) 699 (94.2) reference
CC 42(5.7) 43 (5.8) 0.70 1.10 (0.66-1.83)
A4889G/T6235C
AA+TT 413 (74.5) 438 (76.3) reference
AG+TC 128 (23.1) 123 (21.4) 0.18 1.25 (0.90-1.74)
GG+CC 13 (2.4) 13 (2.3) 0.34 1.59 (0.61-4.15)
AA+TT 413 (71.6) 438 (74.0) reference
AG+GG+TC+CC 164 (28.4) 154 (26.0) 0.14 1.26 (0.93-1.70)
AA+AG+TT+TC 693 (98.1) 697 (98.2) reference
GG+CC 13 (1.9) 13 (1.8) 0.44 1.45 (0.56-3.74)
* : Adjusted odds ratio for age and ethnic origin; a: confidence interval. The significant results are shown in a bold font.
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with a lower risk of BC among Japanese (40) patients.
Furthermore, no association between the CYP1A1 4889AG
polymorphism and BC risk was observed among North
Americans (19-22,30,33,35), Chinese (21,34), Europeans (31),
or Indians (25,28). These discrepant results seem to be due to
ethnic variations among the studied populations because the
CYP1A1 4889AG+GG genotype was both underrepresented
(21,25,28,34,40) and overrepresented (19,20,22,30,31,33,35) in
our controls compared with controls from the other studies.
In our study, the CYP1A1 T6235C polymorphism was not
associated with SBC risk. Although a large number of subjects
were evaluated, the statistical analyses were characterized by a
low statistical power. In addition, the CYP1A1 T6235C
polymorphism did not alter the risk of BC among African-
Americans (30,33), North-Americans (5,21,30,33), Chinese (34),
Indians (25,36), or Brazilians (37). In contrast, Miyoshi et al. (40)
and da Fonte de Amorim et al. (32) reported a lower risk
of BC among Japanese and Brazilian carriers of the C variant
allele. Moreover, an association between the CYP1A1 T6235
C allele and a high BC risk was previously described by Taioli
et al. (20,22), Li et al. (33), Chacko et al. (23), Shen et al. (24),
Gulyaeva et al. (26), Naushad et al. (28) and Khvostova
et al. (29). Discrepancies between the results of our study and
the da Fonte de Amorim study (32) (both studies were
conducted among Brazilians) and discrepancies between
the results of our study and those of Taioli (20,22) and
Naushad (28) (African-American and Indian women, respec-
tively) may be attributed to different sample sizes. We analyzed
742 SBC patients. The studies by da Fonte de Amorim, Taioli
and Naushad analyzed significantly smaller numbers of
patients (n=128, n=57 and n=342, respectively). Conversely,
the discrepancies between our study and the remaining
Table 2 - CYP1A1 genotypes among sporadic breast cancer patients stratified by the clinical features and biological aspects of the
tumor
CYP1A1 A4889G polymorphism
Features Noa AA AG GG AA+AG GG AA AG+GG
Ethnical origin 742
Caucasian 638 444 (69.6) 178 (27.9) 16 (2.5) 622 (97.5) 16 (2.5) 444 (69.6) 194 (30.4)
Non-Caucasian 104 83 (79.8) 17 (16.3) 4 (3.9) 100 (96.1) 4 (3.9) 83 (79.8) 21 (20.2)
p-value 0.01 0.64 0.47 0.03
MAMb 693c
younger than 13 years 298 202 (67.8) 89 (29.9) 7 (2.3) 291 (97.7) 7 (2.3) 202 (67.8) 96 (32.2)
13 years and older 395 289 (73.1) 93 (23.5) 13 (3.4) 382 (96.6) 13 (3.4) 289 (73.1) 106 (26.9)
p-value 0.12 0.58 0.48 0.19
MAFFTPd 692c
younger than 22 years 275 182 (66.2) 82 (29.8) 11 (4.0) 264 (96.0) 11 (4.0) 182 (66.2) 93 (33.8)
22 years and older 417 306 (73.4) 103 (24.7) 8 (1.9) 409 (98.1) 8 (1.9) 306 (73.4) 111 (26.1)
p-value 0.08 0.08 0.11 0.03
Body mass index 708c
Under+normal 253 185 (73.1) 63 (24.9) 5 (2.0) 248 (98.0) 5 (2.0) 185 (73.1) 68 (26.9)
Pre-obese+obese 455 316 (69.5) 125 (27.5) 14 (3.0) 441 (97.0) 14 (3.0) 306 (69.5) 139 (30.5)
p-value 0.29 0.29 0.33 0.21
Histological grade 642c
I+II 93 56 (60.2) 35 (37.6) 2 (2.2) 91 (97.8) 2 (2.2) 56 (60.2) 37 (39.8)
III 549 400 (72.9) 132 (24.0) 17 (3.1) 532 (96.9) 17 (3.1) 400 (72.9) 149 (27.1)
p-value 0.008 0.83 0.62 0.01
CYP1A1 T6235C polymorphism
Features Noa TT TC CC TT+TC CC TT TC+CC
Ethnical origin 742
Caucasian 638 403 (63.2) 202 (31.7) 33 (5.1) 605 (94.9) 33 (5.1) 403 (63.2) 235 (36.8)
Non-Caucasian 104 61 (58.7) 34 (32.7) 9 (8.6) 95 (91.4) 9 (8.6) 61 (58.7) 43 (41.3)
p-value 0.70 0.21 0.20 0.45
MAMb 693c
younger than 13 years 298 181 (60.7) 94 (31.6) 23 (7.7) 275 (92.3) 23 (7.7) 181 (60.7) 117 (39.3)
13 years and older 395 255 (64.6) 124 (31.4) 16 (4.0) 379 (96.0) 16 (4.0) 255 (64.6) 140 (35.4)
p-value 0.78 0.04 0.05 0.37
MAFFTPd 692c
younger than 22 years 275 165 (60.0) 94 (34.1) 16 (5.9) 259 (94.1) 16 (5.9) 165 (60.0) 110 (40.0)
22 years and older 417 263 (63.1) 129 (30.9) 25 (6.0) 392 (94.0) 25 (6.0) 263 (63.1) 154 (36.9)
p-value 0.39 0.93 0.87 0.44
Body mass index 708c
Under+normal 253 159 (62.8) 84 (33.2) 10 (4.0) 243 (96.0) 10 (4.0) 159 (62.8) 94 (37.2)
Pre-obese+obese 455 287 (63.1) 137 (30.1) 31 (6.8) 424 (93.2) 31 (6.8) 287 (63.1) 168 (36.9)
p-value 0.72 0.05 0.04 0.76
Histological grade 642c
I+II 93 48 (51.6) 37 (39.8) 8 (8.6) 85 (91.4) 8 (8.6) 48 (51.6) 45 (48.4)
III 549 352 (64.1) 169 (30.8) 28 (5.1) 521 (94.9) 28 (5.1) 352 (64.1) 197 (35.9)
p-value 0.05 0.07 0.18 0.02
a : number; b: Median age at menarche; c: The total number differs from the total (742) number quoted in the study because it was not possible to obtain
information for some individuals; d: Median age at first full-term pregnancy. The significant results are presented in a bold font.
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discordant studies may be explained by ethnic variation
within the populations because the frequency of the CYP1A1
6235TC+CC genotype was lower (40) or higher (23,24,26,29,33)
among our controls compared to their controls.
Additionally, in our study, the CYP1A1 4889AG and
4889AG+GG genotypes were overrepresented in Caucasian
Brazilian women with BC compared with non-Caucasian
women. The frequencies of the referred genotypes were also
higher among our Caucasian SBC patients than in our
control group. Therefore, Caucasian women carrying the
G allele had a higher risk of SBC development. Our finding is
consistent with the Sergentanis & Economopoulos meta-
analysis (52), which included Caucasian, Chinese and African
populations from 29 eligible studies. We also observed similar
frequencies of the distinct CYP1A1 T6235C polymorphisms
among our Caucasian and non-Caucasian women. To the
best of our knowledge, the association between the CYP1A1
T6235 C allele and a high risk BC was only observed in a
small study of North-Americans, which was conducted by
Taioli et al. (20,22).
We identified a relationship between the CYP1A1 6235CC
genotype and SBC in women who experienced an earlier age
at menarche compared to women who experienced a later
age at menarche, as previously described by Huang et al.
(21,39). In fact, women with early menarche are exposed
to estrogen for a longer period of time, which might amplify
the effect of the CYP1A1 6235CC variant product on
breast tissue. We also surprisingly found that the CYP1A1
4889AG+GG genotype was overrepresented in SBC patients
who experienced their FFTP earlier in life compared to
women who experienced a later FFTP. An early age at FFTP is
well-known to be highly protective against the onset of
BC (11,53,54) and the CYP1A1 A4889G genotype is associated
with an increased BC risk in women with an older age at
FFTP (55,56) because of the prolonged estrogen exposure of
the breast epithelium (6,10). However, Brazilian women are
characterized by a low average FFTP age and also by
multiparity (57), which seem to be protective factors (11).
However, Kobayashi et al. (58) reported that each pregnancy,
including the first one, increases the risk of early onset BC
due to the reaction cascade triggered by chorionic gonado-
tropin hormone (hCG) during the first trimester of pregnancy.
This cascade results in the morphological and functional
development of breast tissue. The high progesterone condi-
tions induced by hCG seem to be essential to pregnancy-
associated breast development, presumably as a result of
mammary epithelial stem cell expansion. This fact, associated
with the high estrogen metabolism among multiparous
women with the G variant allele, may explain our results.
However, we did not determine how many pregnancies each
woman had experienced until BC was diagnosed.
In our study and Huang et al. (21,39), BC risk was higher
among women with a high BMI. In Huang et al., the CC
variant genotype of the CYP1A1 T6235C polymorphism was
overrepresented in pre-obese and obese women, suggesting
that the CC variant might affect BC susceptibility. One plausible
mechanism for this association is that obese women have a
higher circulating estrogen level caused by the conversion of
androgen to estrogen in adipose tissue. Apart from this
possibility, obese women have a higher formation rate of
genotoxic compounds that may lead to DNA adduct formation
in mammary cells (10,11).
Finally, we observed that the G and C variant alleles of
both polymorphisms were positively associated with lower
histological grade tumors, thereby indicating their roles in
the progression of mammary carcinogenesis (even compared
to controls). Thus, carriers of the respective variant alleles of
both polymorphisms have an increased risk of developing
histological grade I and II BC. Conflicting results regarding
the roles of CYP1A1 A4889G and T6235C in the histological
grade of BC have been previously observed in small studies
conducted by Miyoshi et al. (40) (n=195) and Singh et al. (36)
(n=150).
Our data are useful for predicting BC risk. Our results
showed that CYP1A1 A4889G and T6235C polymorphisms
alter the risk and clinical or tumor characteristics of BC among
a heterogeneous population from Southeastern Brazil.
Although this study is not the first study to investigate SBC
in Brazil (32,37), the large sample size provides more reliable
conclusions regarding SBC among Brazilians.
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